TELA Bio Q4 2025 revenue $20.9M (+18% YoY); guides FY26 growth at least 8%

TELA Bio, Inc.

Q4 2025 revenue $20.9M (+18% YoY); FY 2025 revenue $80.3M (+16% YoY).
Net loss Q4 2025 $9.0M vs $9.2M prior year; FY net loss $38.8M vs $37.8M.
Closed $70M credit facility from Perceptive Advisors; $60M drawn at closing, $10M option by Apr 2027.
Promoted Howard Langstein, MD, FACS to Chief Medical Officer effective March 1, 2026.
FY 2026 revenue guidance: at least 8% growth; Q1 2026 revenue expected ~$18.5M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

TELA Bio, Inc. reported financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.

Period: the fourth quarter of 2025 and the fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 24, 2026, TELA Bio, Inc. (the " Company ") issued a press release announcing its financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

TELA Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-033839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.